Literature DB >> 16897662

Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.

Daria Podlekareva1, Amanda Mocroft, Ulrik B Dragsted, Bruno Ledergerber, Marek Beniowski, Adriano Lazzarin, Jonathan Weber, Nathan Clumeck, Norbert Vetter, Andrew Phillips, Jens D Lundgren.   

Abstract

BACKGROUND: Limited data exist on factors predicting the development of opportunistic infections (OIs) at higher-than-expected CD4(+) cell counts in human immunodeficiency virus (HIV) type 1-infected adults.
METHODS: Multivariate Poisson regression models were used to determine factors related to the development of groups of OIs above their respective traditional upper CD4(+) cell count thresholds: group 1 (>or=100 cells/ microL), OIs caused by cytomegalovirus, Mycobacterium avium complex, and Toxoplasma gondii; group 2 (>or=200 cells/ microL), Pneumocystis pneumonia and esophageal candidiasis; and group 3 (>or=300 cells/ microL), pulmonary and extrapulmonary tuberculosis.
RESULTS: In groups 1, 2, and 3, 71 of 9,219, 125 of 7,934, and 36 of 7,838 patients, respectively, developed >or=1 intragroup OI. The strongest predictor of an OI in groups 1 and 2 was current CD4(+) cell count (for group 1, incidence rate ratio [IRR] per 50% lower CD4(+) cell count, 5.37 [95% confidence interval {CI}, 3.71-7.77]; for group 2, 4.28 [95% CI, 2.98-6.14]). Injection drug use but not current CD4(+) cell count predicted risk in group 3. Use of antiretroviral treatment was associated with a lower incidence of OIs in all groups, likely by reducing HIV-1 RNA levels (IRR per 1-log(10) copies/mL higher HIV-1 RNA levels for group 1, 1.50 [95% CI, 1.15-1.95]; for group 2, 1.68 [95% CI, 1.40-2.02]; and for group 3, 1.89 [95% CI, 1.40-2.54]).
CONCLUSION: Although the absolute incidence is low, the current CD4(+) cell count and HIV-1 RNA level are strong predictors of most OIs in patients with high CD4(+) cell counts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16897662     DOI: 10.1086/506366

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Antiretroviral therapy for tuberculosis control in nine African countries.

Authors:  Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

Review 2.  Current progress in the development of RNAi-based therapeutics for HIV-1.

Authors:  J Zhou; J J Rossi
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

3.  Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, Canada.

Authors:  L Lourenço; H Samji; A Nohpal; W Chau; G Colley; K Lepik; R Barrios; V Lima; R S Hogg; Jsg Montaner; S Kesselring; D M Moore
Journal:  HIV Med       Date:  2015-02-27       Impact factor: 3.180

Review 4.  When should antiretroviral therapy for HIV be started?

Authors:  Andrew N Phillips; Brian G Gazzard; Nathan Clumeck; Marcelo H Losso; Jens D Lundgren
Journal:  BMJ       Date:  2007-01-13

5.  Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study.

Authors:  Marlene Smurzynski; Kunling Wu; Constance A Benson; Ronald J Bosch; Ann C Collier; Susan L Koletar
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

6.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

7.  Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy.

Authors:  E Sezgin; M L Van Natta; J E Thorne; M A Puhan; D A Jabs
Journal:  HIV Med       Date:  2018-03-24       Impact factor: 3.180

8.  Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.

Authors:  Kate Buchacz; Bryan Lau; Yuezhou Jing; Ronald Bosch; Alison G Abraham; M John Gill; Michael J Silverberg; James J Goedert; Timothy R Sterling; Keri N Althoff; Jeffrey N Martin; Greer Burkholder; Neel Gandhi; Hasina Samji; Pragna Patel; Anita Rachlis; Jennifer E Thorne; Sonia Napravnik; Keith Henry; Angel Mayor; Kelly Gebo; Stephen J Gange; Richard D Moore; John T Brooks
Journal:  J Infect Dis       Date:  2016-04-18       Impact factor: 5.226

Review 9.  Tuberculosis and illicit drug use: review and update.

Authors:  Robert G Deiss; Timothy C Rodwell; Richard S Garfein
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

10.  Mycobacterium tuberculosis bacteraemia: experience from a non-endemic urban centre.

Authors:  H M El Sahly; L D Teeter; J M Musser; E A Graviss
Journal:  Clin Microbiol Infect       Date:  2013-08-24       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.